Response to clofarabine therapy in pediatric leukemia
. | No. (%) . | . | . | ||
|---|---|---|---|---|---|
| Response . | AML . | ALL . | Total . | ||
| CR | 1 (13) | 4 (24) | 5 (20) | ||
| PR | 2 (25) | 1 (6) | 3 (12) | ||
| HI | 1 (13) | 3 (18) | 4 (16) | ||
| Stable disease | 1 (13) | 3 (18) | 4 (16) | ||
| Early death | 1 (13) | 0 (0) | 1 (4) | ||
| Primary resistance | 2 (25) | 4 (24) | 6 (24) | ||
| Secondary resistance | 0 (0) | 2 (12) | 2 (8) | ||
. | No. (%) . | . | . | ||
|---|---|---|---|---|---|
| Response . | AML . | ALL . | Total . | ||
| CR | 1 (13) | 4 (24) | 5 (20) | ||
| PR | 2 (25) | 1 (6) | 3 (12) | ||
| HI | 1 (13) | 3 (18) | 4 (16) | ||
| Stable disease | 1 (13) | 3 (18) | 4 (16) | ||
| Early death | 1 (13) | 0 (0) | 1 (4) | ||
| Primary resistance | 2 (25) | 4 (24) | 6 (24) | ||
| Secondary resistance | 0 (0) | 2 (12) | 2 (8) | ||
N = 25 patients.
CR indicates complete remission; PR, partial remission, and HI, hematologic improvement.